Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research networkA Ari Hakimi, Irina Ostrovnaya, Boris Reva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced CancerJames J Harding, Andrew X Zhu, Todd M Bauer, et al.
Urologic Oncology|September 12, 2025
Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy aloneDaniel Barbakoff, Mark T Dawidek, Andrea Knezevic, et al.
The Lancet. Oncology|December 25, 2019
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort studyAlejandro Sanchez, Helena Furberg, Fengshen Kuo, et al.
Urologic Oncology|September 6, 2025
Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinomaStephen W Reese, Daniel Barbakoff, Burcin Agridag Ucpinar, et al.
Cancer Discovery|January 10, 2019
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III TrialA Ari Hakimi, Martin H Voss, Fengshen Kuo, et al.
Journal of the National Cancer Institute|November 29, 2013
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinomaA Ari Hakimi, Helena Furberg, Emily C Zabor, et al.
The Oncologist|February 22, 2017
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic ModelGuillermo de Velasco, Aedín C Culhane, André P Fay, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research networkA Ari Hakimi, Irina Ostrovnaya, Boris Reva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced CancerJames J Harding, Andrew X Zhu, Todd M Bauer, et al.
Urologic Oncology|September 12, 2025
Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy aloneDaniel Barbakoff, Mark T Dawidek, Andrea Knezevic, et al.
The Lancet. Oncology|December 25, 2019
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort studyAlejandro Sanchez, Helena Furberg, Fengshen Kuo, et al.
Urologic Oncology|September 6, 2025
Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinomaStephen W Reese, Daniel Barbakoff, Burcin Agridag Ucpinar, et al.
Cancer Discovery|January 10, 2019
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III TrialA Ari Hakimi, Martin H Voss, Fengshen Kuo, et al.
Journal of the National Cancer Institute|November 29, 2013
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinomaA Ari Hakimi, Helena Furberg, Emily C Zabor, et al.
The Oncologist|February 22, 2017
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic ModelGuillermo de Velasco, Aedín C Culhane, André P Fay, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Pageof 15